DK1641820T3 - Fra RasGap afledt peptid til selektiv at dræbe kræftceller - Google Patents
Fra RasGap afledt peptid til selektiv at dræbe kræftcellerInfo
- Publication number
- DK1641820T3 DK1641820T3 DK04743834T DK04743834T DK1641820T3 DK 1641820 T3 DK1641820 T3 DK 1641820T3 DK 04743834 T DK04743834 T DK 04743834T DK 04743834 T DK04743834 T DK 04743834T DK 1641820 T3 DK1641820 T3 DK 1641820T3
- Authority
- DK
- Denmark
- Prior art keywords
- rasgap
- selectively kill
- cancer cells
- derived peptide
- kill cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- C07K14/4706—Guanosine triphosphatase activating protein, GAP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48369103P | 2003-06-30 | 2003-06-30 | |
PCT/IB2004/002165 WO2005000887A1 (en) | 2003-06-30 | 2004-06-30 | Rasgap derived peptide for selectively killing cancer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1641820T3 true DK1641820T3 (da) | 2008-09-15 |
Family
ID=33552068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04743834T DK1641820T3 (da) | 2003-06-30 | 2004-06-30 | Fra RasGap afledt peptid til selektiv at dræbe kræftceller |
Country Status (17)
Country | Link |
---|---|
US (1) | US8110544B2 (da) |
EP (1) | EP1641820B1 (da) |
JP (1) | JP4887143B2 (da) |
KR (1) | KR101051785B1 (da) |
CN (1) | CN1816564B (da) |
AT (1) | ATE397016T1 (da) |
AU (1) | AU2004251126B2 (da) |
BR (1) | BRPI0411485A (da) |
CA (1) | CA2530613A1 (da) |
DE (1) | DE602004014145D1 (da) |
DK (1) | DK1641820T3 (da) |
EA (1) | EA009524B1 (da) |
ES (1) | ES2308200T3 (da) |
HK (1) | HK1089190A1 (da) |
IL (1) | IL172783A (da) |
MX (1) | MXPA05014078A (da) |
WO (1) | WO2005000887A1 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000887A1 (en) * | 2003-06-30 | 2005-01-06 | Universite De Lausanne | Rasgap derived peptide for selectively killing cancer cells |
WO2008014979A2 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
US9513296B2 (en) | 2006-08-21 | 2016-12-06 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
US9689879B2 (en) | 2006-08-21 | 2017-06-27 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
EP3346005A1 (en) | 2008-01-31 | 2018-07-11 | CureVac AG | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
WO2010037284A1 (zh) * | 2008-09-26 | 2010-04-08 | 武汉凯泰新生物技术有限公司 | 治疗或预防癌症的多肽及其衍生产品和应用 |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20120022000A1 (en) * | 2009-01-30 | 2012-01-26 | Universite De Lausanne | Use of a peptide in the treatment or prevention of metastasis |
CN101891802B (zh) * | 2009-08-11 | 2011-11-16 | 武汉凯泰新生物技术有限公司 | 治疗或预防癌症的多肽或衍生产品及其应用 |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
CN101921313B (zh) * | 2010-04-07 | 2012-02-29 | 武汉凯泰新生物技术有限公司 | 治疗或预防癌症的多肽或其衍生产品及应用 |
AU2011285200B2 (en) | 2010-07-30 | 2014-08-21 | CureVac SE | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
US20130130991A1 (en) * | 2010-08-02 | 2013-05-23 | Universite De Lausanne | Use of a peptide enhancing the ability of radiation therapy to kill cancer cells |
CN102533996B (zh) * | 2012-01-04 | 2013-06-05 | 南通大学附属医院 | 确定人april基因启动子、转录因子结合位点的方法及用途 |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
CN105473158B (zh) | 2013-08-21 | 2021-04-13 | 库瑞瓦格股份公司 | 呼吸道合胞病毒(rsv)疫苗 |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2694296B1 (fr) * | 1992-07-30 | 1994-09-02 | Rhone Poulenc Rorer Sa | Peptides inhibant l'activité des protéines ras, préparation et utilisation. |
FR2729295A1 (fr) * | 1995-01-17 | 1996-07-19 | Rhone Poulenc Rorer Sa | Traitement therapeutique combine des pathologies hyperproliferatives |
FR2780062B1 (fr) | 1998-06-17 | 2000-07-28 | Rhone Poulenc Rorer Sa | Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations |
EP1137664A2 (en) * | 1998-12-10 | 2001-10-04 | Washington University | Protein transduction system and methods of use thereof |
CA2364690A1 (en) * | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
AUPR721101A0 (en) * | 2001-08-23 | 2001-09-13 | University Of Queensland, The | Nucleic acid and polypeptide linked to breast cancer |
WO2005000887A1 (en) * | 2003-06-30 | 2005-01-06 | Universite De Lausanne | Rasgap derived peptide for selectively killing cancer cells |
-
2004
- 2004-06-30 WO PCT/IB2004/002165 patent/WO2005000887A1/en active IP Right Grant
- 2004-06-30 AU AU2004251126A patent/AU2004251126B2/en not_active Ceased
- 2004-06-30 EA EA200600128A patent/EA009524B1/ru not_active IP Right Cessation
- 2004-06-30 AT AT04743834T patent/ATE397016T1/de active
- 2004-06-30 DK DK04743834T patent/DK1641820T3/da active
- 2004-06-30 MX MXPA05014078A patent/MXPA05014078A/es active IP Right Grant
- 2004-06-30 US US10/563,536 patent/US8110544B2/en not_active Expired - Fee Related
- 2004-06-30 KR KR1020057025210A patent/KR101051785B1/ko not_active IP Right Cessation
- 2004-06-30 EP EP04743834A patent/EP1641820B1/en not_active Not-in-force
- 2004-06-30 CN CN2004800185197A patent/CN1816564B/zh not_active Expired - Fee Related
- 2004-06-30 DE DE602004014145T patent/DE602004014145D1/de active Active
- 2004-06-30 CA CA002530613A patent/CA2530613A1/en not_active Abandoned
- 2004-06-30 BR BRPI0411485-0A patent/BRPI0411485A/pt not_active IP Right Cessation
- 2004-06-30 JP JP2006516588A patent/JP4887143B2/ja not_active Expired - Fee Related
- 2004-06-30 ES ES04743834T patent/ES2308200T3/es active Active
-
2005
- 2005-12-22 IL IL172783A patent/IL172783A/en not_active IP Right Cessation
-
2006
- 2006-10-05 HK HK06111033A patent/HK1089190A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2007527856A (ja) | 2007-10-04 |
IL172783A (en) | 2011-12-29 |
JP4887143B2 (ja) | 2012-02-29 |
US8110544B2 (en) | 2012-02-07 |
IL172783A0 (en) | 2006-06-11 |
WO2005000887A1 (en) | 2005-01-06 |
KR101051785B1 (ko) | 2011-07-26 |
BRPI0411485A (pt) | 2006-07-25 |
AU2004251126A1 (en) | 2005-01-06 |
EP1641820B1 (en) | 2008-05-28 |
EP1641820A1 (en) | 2006-04-05 |
DE602004014145D1 (de) | 2008-07-10 |
EA200600128A1 (ru) | 2006-08-25 |
KR20060030486A (ko) | 2006-04-10 |
AU2004251126B2 (en) | 2009-11-12 |
US20060234929A1 (en) | 2006-10-19 |
ES2308200T3 (es) | 2008-12-01 |
CA2530613A1 (en) | 2005-01-06 |
CN1816564A (zh) | 2006-08-09 |
MXPA05014078A (es) | 2006-05-25 |
EA009524B1 (ru) | 2008-02-28 |
HK1089190A1 (en) | 2006-11-24 |
CN1816564B (zh) | 2010-11-24 |
ATE397016T1 (de) | 2008-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1089190A1 (en) | Rasgap derived peptide for selectively killing cancer cells | |
MX2007005521A (es) | Formulaciones estables de peptidos insulinotropicos. | |
CY1113299T1 (el) | Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο | |
EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
IL232501A (en) | Peptide or polypeptide-resistant protein analogs and their uses | |
CY1113948T1 (el) | Θεραπευτικα δραστικα αλφα-msh αναλογα | |
UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
NO20055838D0 (no) | Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
CY1114724T1 (el) | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων | |
ATE398630T1 (de) | Zyklische conotoxin-peptide | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
ATE546462T1 (de) | Peptide und derivate vom apl-typ von hsp60 und pharmazeutische zusammensetzungen | |
DE602004023093D1 (de) | N mit einem abgabemittel in mikronisierter form | |
ATE540971T1 (de) | Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes | |
EA200500871A1 (ru) | Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение | |
WO2001074790A3 (en) | Novel compounds for enhancing chemotherapy | |
ATE521624T1 (de) | Peptide und medizinische zusammensetzungen mit denselben | |
ATE484290T1 (de) | Peptid mit antitumoraler wirkung | |
WO2003092736A3 (en) | Peptide nucleic acid conjugates with transporter peptides | |
TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
WO2005056581A3 (en) | Peptide able to specifically bind a chemokine receptor and use thereof |